This report updates the 2009 recommendations from the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) regarding use of anthrax vaccine in the United States. The report summarizes data on estimated efficacy in humans using a correlates of protection model and safety data and provides updated guidance for use of anthrax vaccine adsorbed for preexposure prophylaxis.
These revised anthrax vaccination recommendations apply to both pre- and post-exposure prophylaxis.
Researchers studied the onset of protection from Anthrax Vaccine Absorbed (AVA) post-exposure prophylaxis (PEP) vaccination and to assess the potential for shortening the duration of treatment.
This document provides clinical guidance for the prophylaxis and treatment of children up to the age of 21 in the event of a deliberate anthrax release.
This article covers antimicrobial post exposure prophylaxis and antimicrobial and antitoxin treatment options. Additionally, it describes potentially beneficial critical care measures for persons with anthrax.